Clinical Trials
23 trialsNCT06524544 2026-05-27
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04579224 2026-05-13
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06857175 2026-04-20
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07322263 2026-04-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Recruiting
NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04895709 2026-04-13
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03575013 2025-12-03
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
Phase 1 Completed
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06632951 2025-08-11
LIVIGNO-3
AbbVie
Phase 2 Active not recruiting
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02426125 2023-08-21
RANGE
Eli Lilly and Company
Phase 3 Completed
NCT03636256 2023-08-14
Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT01780545 2022-07-11
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT02401542 2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2 Terminated
NCT00880334 2018-09-18
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03209206 2017-12-22
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence
Seoul National University Hospital
Phase 2 Unknown
NCT00565227 2016-12-02
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00479089 2015-11-02
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01071928 2015-08-19
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn